Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 18/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700035 | 1.00 | SMYD3 (0.49) | SMYD3ATMKDM4EALDH1A1 | |
| SCHEMBL10182015 | 1.00 | SMYD3 (0.49) | SMYD3ATMKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL29624912 | 0.98 | SMYD3 (0.47) | SMYD3ATMKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL571824 | 0.98 | SMYD3 (0.47) | SMYD3ATMKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL571823 | 0.98 | SMYD3 (0.47) | SMYD3ATMKDM4EALDH1A1 | |
| SCHEMBL13343453 | 0.88 | KMT2A (0.49) | SMYD3ATM | |
| SCHEMBL50350 | 0.87 | — | — | |
| SCHEMBL284342 | 0.87 | ATM (0.56) | ATMKDM4EALDH1A1 | |
| SCHEMBL284319 | 0.87 | ATM (0.56) | ATMKDM4EALDH1A1 | |
| SCHEMBL284318 | 0.87 | ATM (0.56) | ATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | claimed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2012-05-10 | — | — | US | claimed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | claimed |
| US-7683057-B2 | 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1-acetyl-piperidin-4-yl)-amide; inhibition of 5' AMP-activated protein kinase (AMPK) | TYROGENEX, INC. (US) | 2010-03-23 | — | — | US | claimed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| US-20090076005-A1 | Kinase inhibitor compounds | XCOVERY, INC. (US) | 2009-03-19 | — | — | US | claimed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4676931-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250326757-A1 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2025-10-23 | — | — | US | disclosed |
| EP-1076649-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055679-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| US-3980677-A | Anthraquinone dyestuffs containing sulphonic acid groups | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076005-A1 | Kinase inhibitor compounds | MAP3K1, MAP3K20, MAP3K2 | SMYD3 2070/4885ATM 311/4885KDM4E 1241/4885 |
| US-20120115866-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | SMYD3 2070/4885ATM 311/4885KDM4E 1241/4885 |
| US-20250326757-A1 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK3 | SMYD3 1264/4885ATM 329/4885KDM4E 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.